Hims & Hers Health (NYSE:HIMS) Releases Quarterly Earnings Results, Misses Estimates By $0.44 EPS

Hims & Hers Health (NYSE:HIMS) released its quarterly earnings results on Monday. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44), FiscalAI reports. The business had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 5.78% and a negative net margin of 0.56%.The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.20 earnings per share.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Hims & Hers pivoted its weight‑loss strategy to branded GLP‑1s and quickly partnered with Novo Nordisk—fulfilling more than 125,000 Wegovy shipments and signaling it is on track to add north of 100,000 new weight‑loss subscribers per month.
• Q1 showed modest top‑line growth (revenue $608M, +4%; subscribers ~2.6M, +9%) but the company incurred approximately $33 million of restructuring charges (including ~$28M write‑downs) tied to the GLP‑1 compounding pivot, resulting in a GAAP loss of $92M and ~5 percentage points of gross‑margin pressure.
• Management raised 2026 guidance to $2.8–$3.0 billion in revenue and $275–$350 million in adjusted EBITDA (≈11% margin at midpoint), expecting accelerating revenue and EBITDA in H2 as monthly cohorts compound and marketing efficiency improves.
• The company is investing heavily in AI and data infrastructure—building provider and consumer AI copilots, growing an in‑house AI team, and acquiring YourBio for at‑home blood sampling—to strengthen a proprietary data flywheel that management says will deepen engagement and create a durable competitive advantage.
• International expansion is a strategic focus—Hims & Hers expects the Eucalyptus acquisition to close in H2 (≈$240M initial payment) to broaden its global footprint and support its long‑term 2030 targets of at least $6.5 billion revenue and $1.3 billion adjusted EBITDA.

Hims & Hers Health Stock Down 4.7%

Shares of HIMS stock traded down $1.18 during trading on Wednesday, reaching $23.85. The company’s stock had a trading volume of 14,281,164 shares, compared to its average volume of 33,225,484. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43. The stock’s 50-day moving average price is $23.29 and its 200 day moving average price is $29.28. The company has a market capitalization of $5.44 billion, a price-to-earnings ratio of -264.87, a P/E/G ratio of 3.97 and a beta of 2.43. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers lifted its 2026 revenue outlook to $2.8 billion-$3.0 billion and guided Q2 revenue above Wall Street expectations, suggesting demand remains solid despite the near-term disruption.
• Positive Sentiment: Several articles highlighted strong demand for personalized care and management’s view that the business can reaccelerate after the reset, which supports the longer-term growth story.
• Positive Sentiment: Options activity was unusually heavy in call options, indicating some traders are positioning for a rebound.
• Neutral Sentiment: JPMorgan and Bank of America both moved price targets lower, but JPMorgan kept an overweight rating and Bank of America stayed neutral, reflecting a more cautious but not outright bearish stance.
• Neutral Sentiment: Needham raised its target, showing that some analysts still see upside if the company executes on its new mix of products and partnerships.
• Negative Sentiment: Q1 results missed estimates on both earnings and revenue, with Hims & Hers posting a $92.1 million loss versus profit a year ago, which sparked the selloff.
• Negative Sentiment: Management said changes in the GLP-1 weight-loss business hurt margins and disrupted sales recognition, raising concerns about profitability during the transition.
• Negative Sentiment: Lower gross margin and multiple reports describing the stock as plunging after the earnings miss reinforced investor worries that the pivot is pressuring near-term results.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Truist Financial reaffirmed a “hold” rating and issued a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday. Jefferies Financial Group set a $24.50 price target on shares of Hims & Hers Health in a research note on Tuesday. JPMorgan Chase & Co. lowered their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday. Finally, TD Cowen dropped their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a report on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $29.50.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 19,645 shares of the company’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $29.96, for a total transaction of $588,564.20. Following the sale, the chief financial officer owned 262,954 shares of the company’s stock, valued at approximately $7,878,101.84. This represents a 6.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the transaction, the insider owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 204,857 shares of company stock valued at $5,285,706 in the last quarter. Corporate insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the stock. State Street Corp boosted its stake in shares of Hims & Hers Health by 1.8% in the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after buying an additional 132,311 shares during the period. Invesco Ltd. raised its holdings in Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after acquiring an additional 1,600,004 shares in the last quarter. Marex Group plc raised its holdings in Hims & Hers Health by 162.2% in the fourth quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after acquiring an additional 1,496,707 shares in the last quarter. Northern Trust Corp lifted its stake in Hims & Hers Health by 1.4% in the third quarter. Northern Trust Corp now owns 2,415,158 shares of the company’s stock worth $136,988,000 after acquiring an additional 32,236 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Hims & Hers Health by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,398,008 shares of the company’s stock worth $77,863,000 after acquiring an additional 42,569 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.